132 related articles for article (PubMed ID: 31376567)
1. Structure-guided development of purine amide, hydroxamate, and amidoxime for the inhibition of non-small cell lung cancer.
Huang MR; Hsu YL; Lin TC; Cheng TJ; Li LW; Tseng YW; Chou YS; Liu JH; Pan SH; Fang JM; Wong CH
Eur J Med Chem; 2019 Nov; 181():111551. PubMed ID: 31376567
[TBL] [Abstract][Full Text] [Related]
2. Dual-targeting compounds possessing enhanced anticancer activity via microtubule disruption and histone deacetylase inhibition.
Tseng YW; Yang TJ; Hsu YL; Liu JH; Tseng YC; Hsu TW; Lu Y; Pan SH; Cheng TR; Fang JM
Eur J Med Chem; 2024 Feb; 265():116042. PubMed ID: 38141287
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of a new generation of substituted purine hydroxamate analogs as histone deacetylase inhibitors.
Liu R; Wang J; Tang W; Fang H
Bioorg Med Chem; 2016 Apr; 24(7):1446-54. PubMed ID: 26907204
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and pharmacological evaluation of N4,N6-disubstituted pyrimidine-4,6-diamine derivatives as potent EGFR inhibitors in non-small cell lung cancer.
Zhang Y; Lv H; Luo L; Xu Y; Pan Y; Wang Y; Lin H; Xiong J; Guo P; Zhang J; Li X; Ye F
Eur J Med Chem; 2018 Sep; 157():1300-1325. PubMed ID: 30195240
[TBL] [Abstract][Full Text] [Related]
5. Small molecule purine and pseudopurine derivatives: synthesis, cytostatic evaluations and investigation of growth inhibitory effect in non-small cell lung cancer A549.
Bistrović A; Grbčić P; Harej A; Sedić M; Kraljević-Pavelić S; Koštrun S; Plavec J; Makuc D; Raić-Malić S
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):271-285. PubMed ID: 29271659
[TBL] [Abstract][Full Text] [Related]
6. Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities.
Chen Y; Wang X; Xiang W; He L; Tang M; Wang F; Wang T; Yang Z; Yi Y; Wang H; Niu T; Zheng L; Lei L; Li X; Song H; Chen L
J Med Chem; 2016 Jun; 59(11):5488-504. PubMed ID: 27186676
[TBL] [Abstract][Full Text] [Related]
7. Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer.
Song Z; Ge Y; Wang C; Huang S; Shu X; Liu K; Zhou Y; Ma X
J Med Chem; 2016 Jul; 59(14):6580-94. PubMed ID: 26882288
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and structure-activity relationship studies of cytotoxic vinorelbine amide analogues.
Hu L; Song W; Meng Y; Guo D; Liu X; Hu L
Bioorg Med Chem Lett; 2012 Dec; 22(24):7547-50. PubMed ID: 23107481
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and antiproliferative activity of benzofuran-based analogs of cercosporamide against non-small cell lung cancer cell lines.
Bazin MA; Bodero L; Tomasoni C; Rousseau B; Roussakis C; Marchand P
Eur J Med Chem; 2013 Nov; 69():823-32. PubMed ID: 24121233
[TBL] [Abstract][Full Text] [Related]
10. Discovery of 4-anilinofuro[2,3-b]quinoline derivatives as selective and orally active compounds against non-small-cell lung cancers.
Chen YW; Chen YL; Tseng CH; Liang CC; Yang CN; Yao YC; Lu PJ; Tzeng CC
J Med Chem; 2011 Jul; 54(13):4446-61. PubMed ID: 21599000
[TBL] [Abstract][Full Text] [Related]
11. Amides of pyrrole- and thiophene-fused anthraquinone derivatives: A role of the heterocyclic core in antitumor properties.
Tikhomirov AS; Litvinova VA; Andreeva DV; Tsvetkov VB; Dezhenkova LG; Volodina YL; Kaluzhny DN; Treshalin ID; Schols D; Ramonova AA; Moisenovich MM; Shtil AA; Shchekotikhin AE
Eur J Med Chem; 2020 Aug; 199():112294. PubMed ID: 32428792
[TBL] [Abstract][Full Text] [Related]
12. Amide-sulfamide modulators as effective anti-tumor metastatic agents targeting CXCR4/CXCL12 axis.
Wu R; Yu W; Yao C; Liang Z; Yoon Y; Xie Y; Shim H; Bai R
Eur J Med Chem; 2020 Jan; 185():111823. PubMed ID: 31698158
[TBL] [Abstract][Full Text] [Related]
13. Thiophene-3-carboxamide analogue of annonaceous acetogenins as antitumor drug lead.
Kojima N; Fushimi T; Tatsukawa T; Tanaka T; Okamura M; Akatsuka A; Yamori T; Dan S; Iwasaki H; Yamashita M
Eur J Med Chem; 2014 Oct; 86():684-9. PubMed ID: 25226228
[TBL] [Abstract][Full Text] [Related]
14. Discovery of 6-chloro-2-(propylthio)-8,9-dihydro-7H-purines containing a carboxamide moiety as potential selective anti-lung cancer agents.
Zhao TQ; Zhao YD; Liu XY; Wang B; Li ZH; He ZX; Zhang XH; Liang JJ; Ma LY; Liu HM
Eur J Med Chem; 2018 May; 151():327-338. PubMed ID: 29635165
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
[TBL] [Abstract][Full Text] [Related]
16. Salicylketoximes That Target Glucose Transporter 1 Restrict Energy Supply to Lung Cancer Cells.
Granchi C; Qian Y; Lee HY; Paterni I; Pasero C; Iegre J; Carlson KE; Tuccinardi T; Chen X; Katzenellenbogen JA; Hergenrother PJ; Minutolo F
ChemMedChem; 2015 Nov; 10(11):1892-900. PubMed ID: 26332543
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers.
Wang C; Xu S; Peng L; Zhang B; Zhang H; Hu Y; Zheng P; Zhu W
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):203-217. PubMed ID: 30835140
[TBL] [Abstract][Full Text] [Related]
18. New acrylamide-substituted quinazoline derivatives with enhanced potency for the treatment of EGFR T790M-mutant non-small-cell lung cancers.
Liu Z; Wang L; Feng M; Yi Y; Zhang W; Liu W; Li L; Liu Z; Li Y; Ma X
Bioorg Chem; 2018 Apr; 77():593-599. PubMed ID: 29482151
[TBL] [Abstract][Full Text] [Related]
19. Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers.
Lelais G; Epple R; Marsilje TH; Long YO; McNeill M; Chen B; Lu W; Anumolu J; Badiger S; Bursulaya B; DiDonato M; Fong R; Juarez J; Li J; Manuia M; Mason DE; Gordon P; Groessl T; Johnson K; Jia Y; Kasibhatla S; Li C; Isbell J; Spraggon G; Bender S; Michellys PY
J Med Chem; 2016 Jul; 59(14):6671-89. PubMed ID: 27433829
[TBL] [Abstract][Full Text] [Related]
20. Battle tactics against MMP-9; discovery of novel non-hydroxamate MMP-9 inhibitors endowed with PI3K/AKT signaling attenuation and caspase 3/7 activation via Ugi bis-amide synthesis.
Ayoup MS; Fouad MA; Abdel-Hamid H; Ramadan ES; Abu-Serie MM; Noby A; Teleb M
Eur J Med Chem; 2020 Jan; 186():111875. PubMed ID: 31740054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
